Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Sofinnova Partners is a leading European venture capital firm dedicated to life sciences, with a specific focus on healthcare and sustainability. Established in 1972, the firm has a long history of backing innovative entrepreneurs and groundbreaking companies from seed to later-stage. Sofinnova Partners invests in biotechnology, medical devices, and industrial biotechnology sectors, aiming to transform groundbreaking science into tangible solutions for patients and the planet. They operate with a multi-fund strategy covering the entire value chain of life sciences investments.
Central hub for European investment strategy, fund management, portfolio company support, and global operational oversight.
Located in the prestigious 9th arrondissement, near Opéra Garnier, reflecting the firm's established presence in a key European financial center. Modern office facilities designed to foster collaboration and innovation.
Characterized by a deep scientific and financial expertise, a collaborative approach with entrepreneurs, and a long-term vision for value creation in life sciences. The culture encourages rigorous analysis, open debate, and a commitment to ethical investment.
The Paris headquarters is historically significant as the firm's founding location and remains central to its European focus, providing proximity to a rich ecosystem of research institutions, biotech companies, and talent.
While deeply rooted in Europe with offices in Paris, London, and Milan, Sofinnova Partners maintains a global outlook. The firm invests primarily across Europe but also selectively in North America and other key international innovation hubs. Their global network supports portfolio companies with international expansion, access to diverse talent pools, cross-border M&A opportunities, and strategic partnerships worldwide.
7-11 Boulevard Haussmann
Paris
Île-de-France
France
Address: 25 Maddox Street, London W1S 2QN, United Kingdom
Enhances access to UK biotech and medtech innovations, fosters relationships with UK research institutions and entrepreneurs, and supports portfolio companies' European and global expansion.
Address: Via San Prospero 4, 20121 Milan, Italy
Focuses on tapping into Italy's growing innovation landscape in life sciences, supporting local entrepreneurs, and bridging Italian scientific excellence with global venture capital.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sofinnova Partners' leadership includes:
Sofinnova Partners has been backed by several prominent investors over the years, including:
Sofinnova Partners has actively strengthened its team over the past year with key promotions to Partner and strategic hires at the Venture Partner level, enhancing its expertise across various investment strategies including Capital, MD Start, Industrial Biotechnology and Crossover strategies.
Discover the tools Sofinnova Partners uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sofinnova Partners primarily uses the email format consisting of the employee's first initial followed directly by their last name, all at the sofinnovapartners.com domain. This is a common pattern for professional communication within the firm.
flastname@sofinnovapartners.com (e.g., jdoe@sofinnovapartners.com)
Format
apapiernik@sofinnovapartners.com
Example
90%
Success rate
Business Wire / Sofinnova Partners • April 25, 2024
Sofinnova Partners, a leading European life sciences venture capital firm, announced the first closing of its pioneering digital medicine fund, Sofinnova Digital Medicine I, securing €190 million. This fund is dedicated to investing in early-stage companies at the intersection of biology, data, and computation, aiming to foster the next wave of healthcare innovation....more
Sofinnova Partners • January 18, 2024
Sofinnova Partners announced the promotion of Kinam Hong (Capital Strategy) and Guillaume Bray_Ménage (MD Start Strategy) to Partner. These promotions underscore the firm's commitment to nurturing internal talent and reinforcing its specialized investment teams....more
Fierce Biotech / Sofinnova Partners • July 12, 2023
Sofinnova Partners co-led a $60 million Series B financing round for Ablaze Pharmaceuticals, a clinical-stage company focused on developing targeted radiopharmaceutical therapies for cancer treatment. This investment highlights Sofinnova's commitment to advancing innovative oncology solutions with global potential....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sofinnova Partners, are just a search away.